These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 27355941

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
    Saito R, Bringas J, Mirek H, Berger MS, Bankiewicz KS.
    J Neurosurg; 2004 Nov; 101(5):826-31. PubMed ID: 15540922
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG, Marand SV, Geraci S, Pycroft L, Berger FR, Pelletier LA.
    Oncotarget; 2015 Oct 06; 6(30):29456-68. PubMed ID: 26336131
    [Abstract] [Full Text] [Related]

  • 7. Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
    Wang Y, Gao S, Wang W, Liang J.
    Mol Med Rep; 2016 Dec 06; 14(6):5732-5738. PubMed ID: 27878252
    [Abstract] [Full Text] [Related]

  • 8. Characterization of a side population of astrocytoma cells in response to temozolomide.
    Chua C, Zaiden N, Chong KH, See SJ, Wong MC, Ang BT, Tang C.
    J Neurosurg; 2008 Nov 06; 109(5):856-66. PubMed ID: 18976075
    [Abstract] [Full Text] [Related]

  • 9. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 10. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S, Zeng A, Hu Q, Yan W, Liu Y, You Y.
    Neuro Oncol; 2017 Jan 10; 19(1):55-65. PubMed ID: 27471108
    [Abstract] [Full Text] [Related]

  • 11. Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.
    Yan YR, Xie Q, Li F, Zhang Y, Ma JW, Xie SM, Li HY, Zhong XY.
    Neuropathology; 2014 Apr 10; 34(2):128-34. PubMed ID: 24112388
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
    Wang N, Zhang Q, Ning B, Luo L, Fang Y.
    Biomed Pharmacother; 2017 Jun 10; 90():368-374. PubMed ID: 28380412
    [Abstract] [Full Text] [Related]

  • 16. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
    Tang JH, Ma ZX, Huang GH, Xu QF, Xiang Y, Li N, Sidlauskas K, Zhang EE, Lv SQ.
    Exp Cell Res; 2016 May 01; 343(2):148-158. PubMed ID: 27090014
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.